Oculis Holding AG (OCS) Amortization of Deferred Charges (2022 - 2024)
Oculis Holding AG (OCS) posted quarterly Amortization of Deferred Charges of $50410.0 for Q1 2024, up 66.52% year-over-year from $30272.6 in Q2 2023, and down 0.63% quarter-over-quarter from $50731.0 in Q4 2023.
Oculis Holding AG (OCS) Amortization of Deferred Charges (2022 - 2024) Analysis & Trends
Oculis Holding AG's Amortization of Deferred Charges history runs 3 years deep, the most recent figure standing at $50410.0 for Q1 2024.
- In Q1 2024, Amortization of Deferred Charges rose 66.52% year-over-year to $50410.0; the TTM figure through Mar 2024 stood at $201003.6 (changed N/A YoY), while the FY2023 annual figure was $180377.8, up 3.04% from the prior year.
- Amortization of Deferred Charges for Q1 2024 stood at $50410.0, down from $50731.0 in the prior quarter.
- The five-year high for Amortization of Deferred Charges was $50731.0 in Q4 2023, with the low at $30272.6 in Q1 2023.
- The 3-year median for Amortization of Deferred Charges is $49814.7 (2023), against an average of $45629.0.
- The sharpest annual moves came in 2023 and 2024: Amortization of Deferred Charges climbed 11.07% in 2023, then surged 66.52% in 2024.
- Oculis Holding AG's Amortization of Deferred Charges stood at $45673.0 in 2022, then advanced by 11.07% to $50731.0 in 2023, then decreased by 0.63% to $50410.0 in 2024.
- Business Quant data shows OCS's Amortization of Deferred Charges at $50410.0 in Q1 2024, $50731.0 in Q4 2023, and $49814.7 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Oculis Holding AG | 879.09 Mn | 590.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 50,410.02 |
| Mar 31, 2024 | 50,410.02 |
| Dec 31, 2023 | 50,730.95 |
| Dec 31, 2023 | 50,730.95 |
| Sep 30, 2023 | 49,814.71 |
| Sep 30, 2023 | 49,814.71 |
| Jun 30, 2023 | 50,047.90 |
| Jun 30, 2023 | 50,047.90 |
| Mar 31, 2023 | 30,272.55 |
| Mar 31, 2023 | 30,272.55 |
| Dec 31, 2022 | 45,672.96 |
| Dec 31, 2022 | 45,672.96 |
| Sep 30, 2022 | 42,453.72 |
| Sep 30, 2022 | 42,453.72 |